Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 30:13:1620097.
doi: 10.3389/fcell.2025.1620097. eCollection 2025.

Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies

Xiaoran Chen  1 , Jiale Zhou  2 , Xiaoqing Dong  1   2 , Yan Xu  1   2 , Bing Chen  1   2
Affiliations
Review

Regulatory role of E3 ubiquitin ligases in multiple myeloma: from molecular mechanisms to therapeutic strategies

Xiaoran Chen et al. Front Cell Dev Biol. .

Abstract

Multiple myeloma (MM) is a hematological tumor characterized by the malignant proliferation of plasma cells in bone marrow (BM). Despite the prolonged survival of MM patients, a significant amount of patients relapse or become drug resistant. This underlines the importance of the development and investigation of novel targets to improve MM therapy. Increasing evidences have shed light on the emerging roles of E3 ubiquitin ligases in MM. E3 ubiquitin ligases play an essential role in protein ubiquitination, which is involved in the regulation of protein degradation, protein-protein interactions and signal transduction. In this comprehensive review, we will summarize the current understanding of E3 ubiquitin ligases in MM and their contribution to MM therapy, which could help explore the molecular mechanisms in MM and provide potential therapeutic targets for the treatment of MM.

Keywords: E3 ubiquitin ligases; immunity; multiple myeloma; pathogenesis; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The pathogenesis of multiple myeloma.
FIGURE 2
FIGURE 2
The process of ubiquitination.
FIGURE 3
FIGURE 3
Regulatory roles of E3 ubiquitin ligases in MM.
FIGURE 4
FIGURE 4
Regulatory mechanisms of E3 ubiquitin ligases in MM.
FIGURE 5
FIGURE 5
Pharmacological agents targeting the E3 ubiquitin ligases.
See this image and copyright information in PMC

References

    1. Alomari M. (2021). TRIM21 - a potential novel therapeutic target in cancer. Pharmacol. Res. 165, 105443. 10.1016/j.phrs.2021.105443 - DOI - PubMed
    1. Amatangelo M., Flynt E., Stong N., Ray P., Van Oekelen O., Wang M., et al. (2024). Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma. Cell Rep. Med. 5 (6), 101571. 10.1016/j.xcrm.2024.101571 - DOI - PMC - PubMed
    1. Asmamaw M. D., Liu Y., Zheng Y.-C., Shi X. J., Liu H. M. (2020). Skp2 in the ubiquitin-proteasome system: a comprehensive review. Med. Res. Rev. 40 (5), 1920–1949. 10.1002/med.21675 - DOI - PubMed
    1. Barankiewicz J., Salomon-Perzyński A., Misiewicz-Krzemińska I., Lech-Marańda E. (2022). CRL4(CRBN) E3 ligase complex as a therapeutic target in multiple myeloma. Cancers (Basel) 14 (18), 4492. 10.3390/cancers14184492 - DOI - PMC - PubMed
    1. Barrio S., Stühmer T., Da-Viá M., Barrio-Garcia C., Lehners N., Besse A., et al. (2019). Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33 (2), 447–456. 10.1038/s41375-018-0216-8 - DOI - PubMed

LinkOut - more resources